- Home
- Results news
- Vivimed Labs
- Q3 FY26 results
Vivimed Labs Q3 FY26 results: net loss widens to ₹16.55 crore, revenue down 56.2%
Vivimed Labs Limited reported consolidated revenue of ₹15.99 crore and a net loss of ₹16.55 crore for Q3 FY26. EBITDA was a loss of ₹10.92 crore, compared with a loss of ₹7.30 crore in Q2 FY26, while basic EPS was ₹0.88 negative.
Key points
- Revenue was ₹15.99 crore in Q3 FY26, down 56.2% from ₹36.51 crore in Q3 FY25.
- EBITDA was a loss of ₹10.92 crore, with an EBITDA margin of -68.3%, against a profit of ₹1.06 crore and a margin of 2.9% in Q3 FY25.
- Net loss widened to ₹16.55 crore from ₹5.97 crore in Q3 FY25; basic EPS was ₹0.88 negative.
- For 9M FY26, revenue was ₹57.99 crore, down 36.0% from ₹90.66 crore, while the net loss was ₹29.35 crore.
- The stock was down 2.6% on the reaction day, 7.6% by the next day's close and 13.1% by the fifth session's close from the pre-results close.
How did Vivimed Labs perform in Q3 FY26?
Vivimed Labs reported consolidated revenue of ₹15.99 crore in Q3 FY26, down 56.2% from ₹36.51 crore in Q3 FY25 and 22.4% from ₹20.61 crore in Q2 FY26. Total income was ₹15.99 crore, while total expenses were ₹32.54 crore. EBITDA was a loss of ₹10.92 crore and the EBITDA margin was -68.3%.
The company reported a net loss of ₹16.55 crore in Q3 FY26, compared with a net loss of ₹5.97 crore in Q3 FY25 and ₹7.30 crore in Q2 FY26. Basic EPS was ₹0.88 negative, unchanged from Q2 FY26 and lower than ₹0.72 negative in Q3 FY25. On the standalone basis, revenue was ₹11.63 crore and the net loss was ₹16.57 crore.
| ₹ crore | Q3 FY26 | Q2 FY26 | Q3 FY25 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 15.99 | 20.61 | 36.51 | −56.2% | −22.4% |
| Other income | 0 | 0.21 | 0.07 | ||
| Total expenses | 32.54 | 28.13 | 42.55 | −23.5% | +15.7% |
| EBITDA | −10.92 | −0.96 | 1.06 | turned to loss | |
| EBITDA margin | -68.3% | -4.6% | 2.9% | −71.2 pp | −63.7 pp |
| Profit before tax | −16.55 | −7.30 | −5.97 | ||
| Tax | 0 | 0 | 0 | ||
| Net profit | −16.55 | −7.30 | −5.97 | ||
| EPS (₹) | −0.88 | −0.88 | −0.72 |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Vivimed Labs' costs and profit?
Total expenses fell 23.5% to ₹32.54 crore from ₹42.55 crore in Q3 FY25. Cost of materials was lower by ₹5.78 crore at ₹8.93 crore, employee cost was lower by ₹3.60 crore at ₹3.69 crore, and depreciation was lower by ₹1.99 crore at ₹4.63 crore. Finance costs were higher by ₹0.52 crore at ₹1 crore.
Other expenses rose 80.9% to ₹15.32 crore from ₹8.47 crore, while other income declined by ₹0.07 crore to no other income. There was no exceptional item, and tax was unchanged. The filing does not state the reasons for the movements in individual expense lines.
The audited results excerpt includes a qualified conclusion relating to interest, penal interest and penal charges of approximately ₹164.52 million for the quarter ended 31 December 2025 and ₹472.37 million for the year to date. The auditor said these amounts had not been provided for, causing understatement of liabilities and losses and deviating from the accrual principle under Indian accounting standards.
| ₹ crore | Q3 FY26 | Q3 FY25 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 8.93 | 14.71 | −5.78 | −39.3% |
| Employee cost | 3.69 | 7.29 | −3.60 | −49.4% |
| Finance costs | 1 | 0.48 | +0.52 | +108.3% |
| Depreciation | 4.63 | 6.62 | −1.99 | −30.1% |
| Other expenses | 15.32 | 8.47 | +6.85 | +80.9% |
| Total expenses | 32.54 | 42.55 | −10.01 | −23.5% |
| Other income | 0 | 0.07 | −0.07 | |
| Tax | 0 | 0 | 0 |
Source: Company's results filing (XBRL).
How did the first nine months of FY26 go?
For the first nine months of FY26, consolidated revenue was ₹57.99 crore, down 36.0% from ₹90.66 crore in 9M FY25. Total income was ₹58.56 crore, compared with ₹90.81 crore. Profit before tax and net loss were both ₹29.35 crore, against ₹26.36 crore in the year-ago period.
Basic EPS was ₹3.54 negative for 9M FY26, compared with ₹3.18 negative in 9M FY25. The consolidated result was approved by the board on 13 March 2026, alongside the unaudited standalone results and the auditors’ limited review report.
| ₹ crore | 9M FY26 | 9M FY25 | Change |
|---|---|---|---|
| Revenue from operations | 57.99 | 90.66 | −36.0% |
| Profit before tax | −29.35 | −26.36 | |
| Net profit | −29.35 | −26.36 | |
| EPS (₹) | −3.54 | −3.18 |
Source: Company's results filing (XBRL).
How has Vivimed Labs done over the last 8 quarters?
Revenue reached ₹36.51 crore in Q3 FY25, the highest level in the reported series, and fell to ₹15.99 crore in Q3 FY26. The net loss reached ₹16.55 crore in Q3 FY26, while the EBITDA margin fell to -68.3% from -4.6% in Q2 FY26.
The trend shows revenue declining from ₹21.39 crore in Q1 FY26 and ₹20.61 crore in Q2 FY26 to ₹15.99 crore in Q3 FY26. Net profit moved from a loss of ₹5.49 crore in Q1 FY26 and ₹7.30 crore in Q2 FY26 to a loss of ₹16.55 crore in Q3 FY26; the EBITDA margin was -1.3%, -4.6% and -68.3% in those respective quarters.
What did the auditors point out?
The statutory auditors expressed a modified conclusion on the limited review of the consolidated results and a qualified conclusion on the standalone review. The review was not an audit and did not express an audit opinion. The qualified basis states that Vivimed Labs had not provided for interest, penal interest and penal charges of approximately ₹164.52 million for the quarter ended 31 December 2025 and ₹472.37 million for the year to date.
The auditors said they were obtaining direct balance confirmations from banks and that the omission understated liabilities and losses for the reporting period. They also said an extract of a forensic audit report concerning transactions from earlier financial years was being evaluated, with no adjustments made pending completion of that assessment. The excerpt further refers to a provision for commission expenses of ₹46.03 million relating to sales of earlier financial years.
How did Vivimed Labs shares react?
The results were announced after market hours on 13 March 2026. From the pre-results close of ₹6.88, the stock was down 0.1% after five minutes, 2.2% after 15 minutes and 2.6% after 30 minutes. It closed the reaction session down 2.6%.
| After the filing | Stock |
|---|---|
| 5 minutes | −0.1% |
| 15 minutes | −2.2% |
| 30 minutes | −2.6% |
| Reaction day | −2.6% |
| Next day | −7.6% |
| 5 days | −13.1% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
Quick answers
What was Vivimed Labs' revenue in Q3 FY26?
Revenue from operations was ₹15.99 crore, down 56.2% from ₹36.51 crore in Q3 FY25 (consolidated).
Did Vivimed Labs make a profit in Q3 FY26?
No. It reported a net loss of ₹16.55 crore, against a net loss of ₹5.97 crore in Q3 FY25.
What was Vivimed Labs' EPS in Q3 FY26?
Basic loss per share was ₹0.88, against a loss of ₹0.72 in Q3 FY25.
How did Vivimed Labs shares react to the Q3 FY26 results?
On the reaction day the stock moved −2.6% from the previous close.
When did Vivimed Labs announce its Q3 FY26 results?
On 13 March 2026, in a filing to the NSE.
Sources
- Board Meeting Intimation for 31St December 2025 Results (BSE, 2 February 2026) · PDF
- Cancellation of Board Meeting (BSE, 11 February 2026) · PDF
- Board Meeting Intimation for Notice Of Board Meeting (BSE, 9 March 2026) · PDF
- Outcome of Board Meeting (NSE, 13 March 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.